Introducing Opin, Opyl’s AI platform that recruits clinical trial patients from around the world

The launch of Opin, opens the door to millions of motivated and qualified patients who self-select and are then matched to clinical trials, reducing the cost and time to recruit for biopharma and medtech companies saving hundreds of millions of dollars.

“Improving efficiencies in research, creating greater equity, access and opportunities for patients to become more empowered in their health management is our goal,” said Michelle Gallaher, CEO of Opyl.

This is only an excerpt from an article written by Stockhead. The full version can be found here.